GT200600403A - PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS - Google Patents
PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMSInfo
- Publication number
- GT200600403A GT200600403A GT200600403A GT200600403A GT200600403A GT 200600403 A GT200600403 A GT 200600403A GT 200600403 A GT200600403 A GT 200600403A GT 200600403 A GT200600403 A GT 200600403A GT 200600403 A GT200600403 A GT 200600403A
- Authority
- GT
- Guatemala
- Prior art keywords
- pharmaceutical compositions
- dosage forms
- patient
- approximately
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
LA PRESENTE INVENCION SE RELACIONA CON METODO QUE COMPRENDE ADMINISTRAR A UN PACIENTE UNA FORMA DE DOSIFICACION ORAL QUE COMPRENDE LECOZOTAN Y UN PORTADOR FARMACEUTICAMENTE ACEPTABLE Y QUE ALCANZA UNA CONCENTRACION EN PLASMA MAXIMA EN UN PACIENTE Y UNA CONCENTRACION EN PLASMA DE 24 HORAS EN UN PACIENTE, EN DONDE UNA RELACION MEDIA DE CMAX/C24 EN UNA POBLACION DE PACIENTES ES DESDE APROXIMADAMENTE 5:1 HASTA APROXIMADAMENTE 1,1:1.THE PRESENT INVENTION IS RELATED TO A METHOD THAT INCLUDES ADMINISTRATING TO A PATIENT AN ORAL DOSAGE FORM THAT UNDERSTANDS LECOZOTAN AND A PHARMACEUTICALLY ACCEPTABLE CARRIER AND THAT REACHES A CONCENTRATION IN MAXIMUM PLASMA IN A PATIENT AND A CONCENTRATION IN 24 WHERE AN AVERAGE CMAX / C24 RELATIONSHIP IN A PATIENT POPULATION IS FROM APPROXIMATELY 5: 1 TO APPROXIMATELY 1.1: 1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71541705P | 2005-09-09 | 2005-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200600403A true GT200600403A (en) | 2007-09-19 |
Family
ID=37836444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200600403A GT200600403A (en) | 2005-09-09 | 2006-09-06 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1928863A2 (en) |
JP (1) | JP2009507850A (en) |
KR (1) | KR20080043855A (en) |
CN (1) | CN101258146A (en) |
AR (1) | AR058033A1 (en) |
AU (1) | AU2006287543A1 (en) |
BR (1) | BRPI0615771A2 (en) |
CA (1) | CA2620491A1 (en) |
CR (1) | CR9800A (en) |
EC (1) | ECSP088236A (en) |
GT (1) | GT200600403A (en) |
IL (1) | IL189827A0 (en) |
NO (1) | NO20081100L (en) |
PE (1) | PE20070334A1 (en) |
RU (1) | RU2008108216A (en) |
TW (1) | TW200800198A (en) |
WO (1) | WO2007030589A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
CN101553217A (en) | 2005-07-06 | 2009-10-07 | 塞普拉科公司 | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment |
JP2012526832A (en) * | 2009-05-13 | 2012-11-01 | スノビオン プハルマセウトイカルス インコーポレイテッド | Composition comprising transnorsertraline and serotonin receptor 1A agonist / antagonist and use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL203217B1 (en) * | 2000-09-29 | 2009-09-30 | Solvay Pharm Bv | Ion-strength independent sustained release pharmaceutical formulation |
GB2407498B (en) * | 2003-10-30 | 2008-06-11 | Cipla Ltd | Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient |
US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
CN101137648A (en) * | 2005-03-01 | 2008-03-05 | 惠氏公司 | Crystalline and amorphous 4-cyano-n-{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin -1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride |
-
2006
- 2006-09-06 PE PE2006001076A patent/PE20070334A1/en not_active Application Discontinuation
- 2006-09-06 EP EP06790193A patent/EP1928863A2/en not_active Withdrawn
- 2006-09-06 CA CA002620491A patent/CA2620491A1/en not_active Abandoned
- 2006-09-06 WO PCT/US2006/034813 patent/WO2007030589A2/en active Application Filing
- 2006-09-06 KR KR1020087007106A patent/KR20080043855A/en not_active Application Discontinuation
- 2006-09-06 AR ARP060103880A patent/AR058033A1/en unknown
- 2006-09-06 JP JP2008530186A patent/JP2009507850A/en not_active Withdrawn
- 2006-09-06 AU AU2006287543A patent/AU2006287543A1/en not_active Abandoned
- 2006-09-06 CN CNA2006800328607A patent/CN101258146A/en active Pending
- 2006-09-06 TW TW095132852A patent/TW200800198A/en unknown
- 2006-09-06 GT GT200600403A patent/GT200600403A/en unknown
- 2006-09-06 BR BRPI0615771-8A patent/BRPI0615771A2/en not_active Application Discontinuation
- 2006-09-06 RU RU2008108216/14A patent/RU2008108216A/en not_active Application Discontinuation
-
2008
- 2008-02-28 IL IL189827A patent/IL189827A0/en unknown
- 2008-03-03 NO NO20081100A patent/NO20081100L/en not_active Application Discontinuation
- 2008-03-04 EC EC2008008236A patent/ECSP088236A/en unknown
- 2008-03-07 CR CR9800A patent/CR9800A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2620491A1 (en) | 2007-03-15 |
CR9800A (en) | 2008-04-28 |
CN101258146A (en) | 2008-09-03 |
RU2008108216A (en) | 2009-10-20 |
AU2006287543A1 (en) | 2007-03-15 |
BRPI0615771A2 (en) | 2011-05-24 |
PE20070334A1 (en) | 2007-05-08 |
TW200800198A (en) | 2008-01-01 |
EP1928863A2 (en) | 2008-06-11 |
ECSP088236A (en) | 2008-04-28 |
AR058033A1 (en) | 2008-01-23 |
WO2007030589A2 (en) | 2007-03-15 |
KR20080043855A (en) | 2008-05-19 |
NO20081100L (en) | 2008-06-03 |
JP2009507850A (en) | 2009-02-26 |
WO2007030589A3 (en) | 2007-11-01 |
IL189827A0 (en) | 2008-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066534A (en) | DOSAGE FORMS OF CONTROLLED OXYCODONE, ORALS, ONCE A DAY | |
CL2017000669A1 (en) | Pharmaceutical dosage form (divisional of the application 1029/2014) | |
WO2007016563A3 (en) | Alcohol resistant pharmaceutical formulations | |
UA89220C2 (en) | Method for treatment of hiv/aids by administration of solid pharmaceutical dosage formulation comprising a hiv protease inhibitor in fasted state | |
NO20062504L (en) | Compositions and dosage forms for improved absorption | |
TW200510375A (en) | New compounds | |
ECSP055726A (en) | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BASIC EXCIPIENTS | |
CY1111470T1 (en) | NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A | |
JP2005532372A5 (en) | ||
ECSP056229A (en) | A PHARMACEUTICAL COMPOSITION THAT INCLUDES POLYMODIC FORMS OF 3- (4-AMINO-1-OXO-1.3 DYHIDRO-ISOINDOL-2-IL) -PIPERIDINA-2,6-DIONA FOR THE TREATMENT AND HANDLING OF CANCERES | |
RS53209B (en) | Pharmaceutical composition for a hepatitis c viral protease inhibitor | |
ATE337793T1 (en) | DISPERSIBLE PHARMACEUTICAL COMPOSITION OF AN ANTI-INFLAMMATORY | |
NO20074109L (en) | Intravenous formulations of PDE-5 inhibitors | |
UY28525A1 (en) | ACTIVE MACROCICLIC PEPTIDES AGAINST HEPATITIS C VIRUSES | |
UY28281A1 (en) | PHARMACEUTICAL PRODUCTS | |
EA200700855A1 (en) | SPACER | |
DE60334773D1 (en) | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES | |
CY1113462T1 (en) | DOSAGE FORM CONTENTS Pantoprazole as an Active Ingredient | |
NO20062605L (en) | Pharmaceutical formulation containing flavoring substances with improved pharmaceutical properties | |
ATE369139T1 (en) | HIGH DOSE IBANDRONATE FORMULATION | |
HUP0401200A2 (en) | Pharmaceutical compositiuons containing terbinafin and process for producing them | |
DE60102590D1 (en) | PHARMACEUTICAL FORMS FOR TREATING ORAL MYCOSIS | |
TW200733954A (en) | Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same | |
GT200600403A (en) | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | |
RS51115B (en) | Oral formulations of cladribine |